This research is Trending!
New Evidence in Heart Failure: 2026 Update
Why the study?
Heart failure remains a major cause of morbidity, mortality, and healthcare expenditure with an increasing global burden, alongside an accelerating pace of scientific progress across epidemiology, diagnostics, and management.
Design
Review
Key result
Recent advances in heart failure diagnostics and therapeutics support a transition toward a more personalized and biologically informed model of care.
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The mildly reduced LVEF phenotype was introduced in previous guidelines to focus on patients not usually included in clinical trials. Education and lifestyle advice empower patients to manage their heart failure and engage in shared decision-making.”
“There's a reclassification of the nomenclature. We're not using any more reduced or mildly reduced or preserved rejection fraction, we're now going reduce EF less than 50% ejection fraction or preserve ejection fraction more than 50%. Also, there is a new nomenclature for drug therapies... we're not seeing any more guideline or medical therapy, there's now foundational medical therapies.”
Overview
May guide future personalized HF strategies; leaves open the need for prospective validation across phenotypes.
Key Points
- Provide a comprehensive update on evolving epidemiology, pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic paradigms in heart failure management.
- Synthesized contemporary evidence on heart failure classification, including heart failure with reduced and preserved ejection fraction.
- Evaluated diagnostic tools spanning artificial intelligence, multi-omics, advanced imaging, and disease-specific aetiologies.
- Reviewed novel pharmacotherapies including sodium-glucose cotransporter-2 inhibitors, finerenone, and incretin-based agents.
- Mechanistic research underscores the central roles of chronic inflammation, immune activation, metabolic dysfunction, and multi-organ cross-talk in disease progression.
- Therapeutic advances have expanded treatment options across ejection fraction spectra through guideline-directed medical therapy, novel metabolic modulators, and transcatheter interventions.
- Modern management is shifting from empirical ejection fraction classification toward individualized, biologically guided interventions to improve outcomes.
PICO
P
Population
Heart failure
Recent advances in heart failure epidemiology, diagnostics, and therapeutics support a transition towards a more personalized and biologically informed model of care across the entire HF spectrum.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Trending Research#7 this week
A comprehensive review summarizing recent major advances in heart failure therapies and diagnostics, serving as a key reference for clinicians.
Social attention
70
Preprint velocity
0
News coverage
60
Conference
0
Expert commentary
0
Cite This Study
Liguori et al. (2026) conducted a review in Heart failure. Recent advances in heart failure diagnostics and therapeutics support a transition toward a more personalized and biologically informed model of care.